Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
folate-targeted liposomal methotrexate
- Development stage
- Preclinical
- Lead developer
- SOLFARCOS
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Folate-targeted liposomal methotrexate is an experimental nanomedicine developed by Solfarcos for the treatment of rheumatoid arthritis (RA). The formulation consists of methotrexate encapsulated within liposomes that are surface-functionalized with folate ligands. This design exploits the overexpression of folate receptor beta (FR-β) on activated macrophages, which are key drivers of synovial inflammation in RA. By selectively targeting these cells, the drug aims to enhance therapeutic efficacy within the joints while minimizing the systemic adverse effects typically associated with conventional methotrexate therapy, such as gastrointestinal toxicity and hepatotoxicity. Once internalized by the target cells, methotrexate acts as a dihydrofolate reductase (DHFR) inhibitor, disrupting folate metabolism and suppressing inflammatory responses.
- Other names
- folate-based liposomal methotrexateF-Lipo-MTXfolate-functionalized liposomal methotrexatefolate-targeted methotrexate liposomes
02
Targets
DHFR (Dihydrofolate reductase)FOLR2 (Folate receptor beta)
Beyond the preview
Go deeper on folate-targeted liposomal methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on folate-targeted liposomal methotrexate.